Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
WAYNE, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the publication of a systematic review in Clinical and Experimental Dermatology which synthesizes available published clinical evidence on off-label statin use for cutaneous application in porokeratosis. The systematic review supports the scientific rationale and clinical potential for developing Palvella's QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis (DSAP), currently anticipated to enter Phase 2 development in the second half of 2026.
